Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX 5 35 SULFITE FREE IN DEXTROSE 35 IN PLASTIC CONTAINER versus EPANOVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX 5 35 SULFITE FREE IN DEXTROSE 35 IN PLASTIC CONTAINER versus EPANOVA.
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER vs EPANOVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids and dextrose for protein synthesis and energy metabolism in parenteral nutrition. Dextrose supplies glucose for cellular energy, while amino acids serve as substrates for protein synthesis.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Intravenous administration of 5% amino acids (Clinimix 5/35 refers to 5% amino acids, not 35%; 35% dextrose is not a standard concentration in Clinimix products; assuming a standard Clinimix product: Clinimix 5/35 is not a known concentration; typical Clinimix is 5% or 8% amino acids with varying dextrose concentrations; for this response, considering Clinimix 5/15 or similar; if interpreting as dextrose 35%, that is not possible; assuming correct product is Clinimix 5% amino acids with dextrose, typical adult dose is based on protein requirements: 1-2 g amino acids/kg/day, corresponding to 20-40 mL/kg/day of a 5% amino acid solution, administered as a continuous IV infusion. Maximum infusion rate is generally 4 mg/kg/min for amino acids.
4 g orally once daily as 4 capsules of 1 g each with food.
None Documented
None Documented
Amino acids: 0.5-1 h (rapid distribution and metabolism); glucose: ~1.5-2 h (insulin-dependent). Clinical context: continuous infusion maintains steady state.
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Renal: 90-100% as free amino acids and glucose metabolites; <5% biliary/fecal.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution